Extracellular Vesicles as Biomarkers in Cardiovascular Disease;Chances and Risks by Dickhout, Annemiek & Könen, Rory R.
REVIEW
published: 22 August 2018
doi: 10.3389/fcvm.2018.00113
Frontiers in Cardiovascular Medicine | www.frontiersin.org 1 August 2018 | Volume 5 | Article 113
Edited by:
Cihan Ay,
Medizinische Universität Wien, Austria
Reviewed by:
Johannes Thaler,
Medizinische Universität Wien, Austria
Adriana Georgescu,
Institute of Cellular Biology and
Pathology (ICBP), Romania
*Correspondence:
Rory R. Koenen
r.koenen@maastrichtuniversity.nl
Specialty section:
This article was submitted to
Atherosclerosis and Vascular
Medicine,
a section of the journal
Frontiers in Cardiovascular Medicine
Received: 23 April 2018
Accepted: 06 August 2018
Published: 22 August 2018
Citation:
Dickhout A and Koenen RR (2018)
Extracellular Vesicles as Biomarkers in
Cardiovascular Disease; Chances and
Risks. Front. Cardiovasc. Med. 5:113.
doi: 10.3389/fcvm.2018.00113
Extracellular Vesicles as Biomarkers
in Cardiovascular Disease; Chances
and Risks
Annemiek Dickhout 1 and Rory R. Koenen 1,2*
1Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht, Netherlands, 2 Institute for
Cardiovascular Prevention, Ludwig-Maximilians-Universität München, Munich, Germany
The field of extracellular vesicles (EV) is rapidly expanding, also within cardiovascular
diseases. Besides their exciting roles in cell-to-cell communication, EV have the potential
to serve as excellent biomarkers, since their counts, content, and origin might provide
useful information about the pathophysiology of cardiovascular disorders. Various studies
have already indicated associations of EV counts and content with cardiovascular
diseases. However, EV research is complicated by several factors, most notably the
small size of EV. In this review, the advantages and drawbacks of EV-related methods
and applications as biomarkers are highlighted.
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INTRODUCTION
After having been disregarded for decades, extracellular vesicles (EV) are now in sharp focus
as mediators of cell-to-cell communication and their importance is currently being investigated
for many diseases. Progress is quick, particularly in the field of tumor biology, but also in other
areas e.g., cardiovascular diseases, EV-related findings are gathering strong interest (1–3). Being
identified as mere cellular “dust” in the 1960s, it has become clear that EV are much more
than that. Extracellular vesicles are derived from parent cells and tissues and can be classified
into roughly 3 classes: (I) microvesicles that originate from budding of the cell membrane, (II)
exosomes, that have endosomal/intracellular organelle origin and (III) apoptotic bodies, that are
generated during programmed cell death. However, there appears to be quite some overlap between
those classifications, in a sense that microvesicles can be in the size range of exosomes or vice
versa and/or carry supposed endosomal markers (4). All body fluids have been found to contain
EV, hinting toward their abundance and their possible physiologic roles. In addition, given the
specific cellular origin of the EV, they may contain interesting information, reflecting cellular
functions or health status and thus ultimately revealing physiologic or pathophysiologic disease
states. This would make EV excellent biomarkers. Whereas most biomolecular biomarkers (e.g.,
circulating proteins) do not contain information about the original cellular and tissue context, such
information is often contained in EV, in the form of a palette of cell-specific surface markers and
corresponding membrane-enclosed EV content. A sole determination of the cellular origin of EV
e.g., in plasma could provide information about the nature, severity and prognosis of a particular
disorder. A further perspective is offered by the analysis of the content of EV from patient specimen,
since proteins or nucleic acids within EV can yield clues about the pathophysiologic mechanisms
underlying the disease. The range of cardiovascular pathologies in which EV are suspected to play a
role is very wide and still expanding. However, as the field of EV is still developing, the methods for
optimal analysis of EV determination, purification, and analysis are heavily debated. As established
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biomarkers such as circulating proteins have validated methods
(e.g., ELISA) and clearly defined pre-analytical variables (e.g.,
concerning sample preparation), these are much less clearly
defined in the field of EV. In this overview, the current
chances and risks of the use of EV as biomarkers will be
discussed.
ISOLATION AND MEASUREMENT OF
EV—ARE WE GETTING CLOSER TO A
GOLD STANDARD?
Isolation of EV
At first sight, the isolation of EV from biologic fluids appears
rather straightforward. In theory, EV can be isolated to purity
solely based on their physicochemical properties, because they
are larger in size than the protein fraction yet smaller than
whole cells, more dense than the lipid fraction, with a rather
defined density range and quite robust due to their membrane
encapsulation. In addition to these physical properties, EV
possess a palette of surface markers specific for the parent cell
type. Thus, there are many possible approaches for EV isolation
(summarized in Table 1). The most widely used method remains
centrifugation in its variants density gradient, differential and
ultracentrifugation. The small size of EV is exploited in a
number of sequential centrifugation steps, starting at low speed
(300 g) to remove any intact cells and continuing at higher
speeds to obtain fractions enriched in microvesicles (20,000 g)
and exosomes (100,000 g). The sedimentation behavior of EV
can be modified by using density gradients, allowing separation
from proteins and other components. Although processing times
can be quite long, a clear advantage of centrifugation is the
possibility to process larger volumes, such as collected cell culture
supernatants. The use of centrifugation is somewhat losing its
popularity since the report of (lipo)protein and/or RNA-protein
complex contaminations and loss of EV integrity after pelleting
(5, 6).
Gaining ground is size-exclusion chromatography (SEC),
which is a quick and straightforward method for removing
proteins and other contaminations from EV-containing fluids.
Columns for SEC can be ordered commercially or easily cast in
the lab, using common 10–50mL syringes, SEC-medium and fine
gauze to retain the gel in the column. Depending on the column
length (and diameter), they can handle volumes in the mL range,
although the use of a large column inherently leads to dilution of
the EV-containing eluate. There is still some debate whether SEC-
purified EV are free of (lipo)protein contaminations (7, 8) and it
is recommended to perform appropriate controls. Conventional
and ultrafiltration has also been used successfully to isolate
EV (9). The principle is similar to SEC, as EV are separated
based on their size properties. In a recent study, the use of
a set of sequential filters with different pore sizes resulted in
preparations of pure and size-defined EV (10). Although the filter
system described in this study is custom made and thus not
commercially available (as many published experimental setups),
the approach appears to have potential to become a standard
method for EV isolation.
TABLE 1 | Overview of current isolation methods of EV from plasma.
Isolation method Principle Advantages (A)/Drawbacks (D)
Differential
centrifugation
Sedimentation
and/or density
A: Large volumes can be processed
A: Widely used and facile method
D: Risk of contaminations with
plasma proteins
D: Risk of EV aggregation/loss of
integrity
D: Quality depends on rotor type
Size exclusion
chromatography
Size (largest elute
first)
A: Well-accepted and facile method
A: Good separation/recovery of EV
A: Preserves integrity of EV
D: Sample volumes small to medium
D: Does not discriminate between EV
origins
D. results in sample dilution
Filters Size A: Processing of large volumes
possible
A: Allows size fractionation of EV
D: Does not discriminate between EV
origins
D. risk of EV fragmentation
Microfluidics Physical behavior
of EV (size)
A: High sample recovery
A: Suitable for small sample volumes
A: Maintains EV integrity and
properties
D: Low sample throughput
D: Not appropriate for large volumes
D: Need of equipment for flow cell
construction
ExoQuickTM Precipitation using
polyethylene glycol
A: Quick and straightforward sample
handling
A: Can be scaled up for larger
samples
A: Amenable to larger sample
numbers
D: Risk for contaminations with
plasma proteins
Magnetic
beads/affinity
chromatography
Immuno-affinity by
surface markers
A: Discriminates between EV origins
A: Less contamination with plasma
proteins
A: Amenable to larger sample
numbers
D: Does not discriminate between EV
sizes
D: Often needs highly specific
antibodies
Fluorescence-
activated cell
sorting (FACS)
Light scattering,
fluorescence
A: Size- and surface marker-based
sorting
D: Long processing times
D: Costly equipment
Considering the increasing interest in microfluidics, it is not
surprising that this principle is implemented in the design of
novel EV isolation techniques [reviewed in Gholizadeh et al.
(11)]. An elegant study made use of microfluidic mixing cells in
combination with visco-elastic sheath fluids, in which the smaller
exosomes were driven to the walls of the flow cells, while larger
particles (microvesicles) and the sample fluid remained in the
center of the flow path. The 3 fluid streams (from the 2 walls and
the center) were collected separately and the 2 sample streams
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originating from the walls contained the isolated exosomes (12).
The recovery of EV was found to be very high using this method,
yet the actual setup is still designed for small sample volumes
and low throughputs. Another widespread method for EV, and
particularly exosome isolation is precipitation. Here, polymers
(e.g., polyethylene glycol) and proprietary chemicals are used to
cause specific precipitation of EV by disturbing the solvation
layer around the membranes. Although this method is quickly
and easily performed on low as well as higher sample volumes,
there is a considerable risk of co-precipitation of contaminants.
All techniques mentioned above are based on the
physicochemical characteristics of EV (e.g., size, surface
potential, density) and inherently do not distinguish between
different cellular origins. Yet since EV also share many cellular
(surface) markers with their parent cells, the opportunity is
created to specifically isolate EV using these markers (see
below). Thus, the use of affinity chromatography or labeled
magnetic beads is an attractive alternative or a complement
to physical techniques such as centrifugation and SEC. One
study took advantage of the binding affinity of EV for heparin
and could enrich EV from biologic samples using heparin
coupled to agarose, which is a commonly used reagent in protein
purifications (13). Although this method is straightforward
and resulted in highly enriched EV preparations, there are
many abundant plasma and serum proteins with high affinity
for sulfated glycosaminoglycans, e.g., antithrombin, CXCL4,
and apolipoproteins. A higher level of specificity can be
achieved by using antibodies against specific surface markers to
isolate EV. Needless to say, this requires markers unique for a
particular EV subset and corresponding antibodies with high
specificity. The potential to separate exosomes from extracellular
vesicles depends on the cellular origin of the EV preparations
(e.g., the exosome marker CD9 is present both on exosomes
and microvesicles from platelets). However, physicochemical
separation principles can be used to enrich or deplete the
EV preparations in/from exosomes prior to implementing
an affinity-based isolation method. Alternatively, EV have
been sorted using sorting by FACS, combining scattering and
marker-based detection methods (14). However, apart from the
limitations described below, a modern FACS sorter might not be
accessible due to high costs and the processing times per sample
might be quite long.
Taken together, there is as yet no golden standard for EV
isolation. The optimal method of EV purification depends, as
often, on the characteristics of the starting material and the
demands of the downstream applications. The good news in this
respect is that many, often multidisciplinary research groups are
in the course of developing innovative methods to achieve high
quality EV preparations.
Measurement and Characterization of EV
A similar story can be told for the measurement and isolation
of EV. The distinct properties of EV can likewise be used to
measure and characterize EV. A summary of the current methods
is summarized in Table 2. In general, their small dimensions and
rather heterogeneous size distribution rather hampers accurate
measurement of EV (15). This particularly applies for flow
TABLE 2 | Overview of current measurement principles of EV.
Detection
method
Principle Advantages (A)/Drawbacks (D)
Flow cytometry Light scattering,
fluorescence
A: Fast recording and high throughput
A: Combined size and surface marker
analysis
D: Limited possibilities using older
machines
D: Artifacts possible due to swarm
detection
Tunable resistive
pulse sensing
Coulter effect
(electrical
resistance
changes)
A: Feasible and accurate size
determination
D: Membranes may clog
D: Accurate measurements are slow
Nanoparticle
tracking analysis
Light scattering,
(fluorescence)
A: Feasible and accurate size
determination
D: Requires careful calibration
D: Accurate measurements are slow
Dynamic light
scattering and
Raman
spectroscopy
(In-)elastic light
scattering
A: Feasible and accurate size
determination
A: Raman yields information about
composition
D: Low throughput
D: Requires high technical proficiency
Transmission
electron
microscopy
Transmission of
accelerated
electrons
A: Size and structure determination
A: Yields impressive images
D: Low throughput
D: Requires high technical proficiency
Atomic force
microscopy
Power exerted to
cantilever
A: Size and structure determination
A: Gives information about surface
markers
D: Low throughput
D: Requires high technical proficiency
Enzyme-linked
immunosorbent
assay
Antigen binding to
antibodies,
fluori-/colorimetric
A: Highly specific and facile method
A: High throughput
D: Limited information about counts
and size
Western blotting Antigen binding to
antibodies,
chemiluminescence
A: Facile method for composition
analysis
A: Medium throughput
D: Limited information about counts
and size
Surface plasmon
resonance
Proteins binding to
ligands,
A: Highly specific and facile method
A: High throughput
D: Limited information about counts
and size
D: Rather expensive and specialized
equipment
cytometry, as older generation machines (that are still commonly
used) generally lack the capability to (accurately) measure
particles sized below 300 nm. Another complication is the low
refractive index of EV and thus the rather low capability to scatter
light in aqueous solutions. In addition, common cytometer optics
poorly distinguish single EV from EV swarms, which complicates
the exact determination of EV counts in samples (16). On the
other hand, modern flow cytometers have optics that allow the
measurement of single particles as small as 100 nm and combined
with careful apparatus setup and parameter adjustment (the
authors refer to www.exometry.com), reliable characterization of
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EV using flow cytometry is possible. This, combined with the use
of fluorescently-labeled antibodies and the high throughput of
the method, makes flow cytometry still a method of choice for
EV determinations.
Two other commonly used techniques are tunable resistive
pulse sensing (TRPS) and nanoparticle tracking analysis (NTA).
The former is based on the current of ions over a permeable
membrane with pores that have tunable size. Particles that block
the pores result in increased membrane resistance, from which a
distribution of size and numbers can be derived. The method is
quite reliable over a range of EV sizes and concentrations, yet care
should be taken not to clog the pores of themembrane or to apply
excessive pressure (15). The detection of EV by NTA is based
on light scattering combined with recording of their Brownian
motion paths using a microscope-camera setup. Knowing the
viscosity and temperature of the sample medium, the EV size
can be derived from their diffusion coefficients calculated using
the Stokes-Einstein equation. A prerequisite is that viscosity and
temperature are exactly defined and that themachine is calibrated
using particles that have similar size and scatter characteristics as
the EV analyzed (15, 17). Nevertheless, the inaccuracies in EV
counts obtained by NTA can be quite high, but protocols have
been developed to minimize sample-to-sample variations (18,
19). A similar technique is dynamic light scattering, which like
NTA is based on elastic Rayleigh scattering and makes use of the
Stokes-Einstein equation for calculating the diffusion coefficients.
A further with potential method is Raman spectroscopy, which is
based on inelastic light scattering making this method attractive
also for analyzing EV, since inelastic light scattering contains
information about the molecular composition of the EV (17, 20).
Drawbacks are the high technical and mathematical complexity
of the method and the long processing times of the analyses.
The same may apply for electron microscopy. Although
electron micrographs of EV preparations are recommended
to be included in EV-focused publications, the proper
sample preparation and recording of (transmission) electron
micrographs of EV requires a high level of technical proficiency.
The images do reveal useful information about EV ultrastructures
and if combined with immunologic detection methods
(immunogold labeling), even information about molecular
composition may be obtained. An interesting evolution of
electron microscopy is cryo-electron tomography, in which
a series of electron micrographs is recorded at various angles
and then composed to a 3D image (21). A recent study has
proven cryo-electron tomography to be feasible for EV, at
least those derived from platelets, revealing a surface covered
with platelet receptors linked to the actin cytoskeleton (22).
A final non-optical microscopy method worth discussing is
atomic force microscopy [reviewed in Sharma et al. (23)]. The
technique works by a microscopic tip at the end of a cantilever
that scans (surface immobilized) biologic specimen, somewhat
like a microscopic turntable. The force exerted on the tip and
cantilever is used to reconstruct an image of the specimen. The
microscope can be set in various modes, each with their specific
properties for obtaining information. Major advantages of this
technique are that it is optimally suited for nanoscale specimen
and that both structural features and information about surface
molecules can be recorded, as the tips can be functionalized with
specific antibodies.
Besides physical (optical) techniques, EV can also be
determined using biochemical (immunologic and enzymatic)
techniques. By making use of the presentation of negatively
charged phospholipids (notably phosphatidyl serine) on their
surface, EV can be captured e.g., using immobilized annexin A5
and subsequent detection using the prothrombinase reaction,
which is highly dependent on negatively charged phospholipids
(24). However, since not all EV express phosphatidyl serine,
a significant fraction might be missed using this method. In
addition to enzymatic assays, immunologic methods or “bulk
immunologic assays” (BIA) might also be applied (25). The many
surface molecules presented on EV and their small size can
be exploited to design specific ELISAs for EV subgroups. In
addition, EV content can be resolved on SDS PAGE gels followed
by western blotting. A more sophisticated method is surface
plasmon resonance spectroscopy, which measures refractory
index changes as a result of mass bound to a golden surface
under flow conditions. When the surfaces are functionalized
with specific antibodies against EV surface markers, EV can be
measured specifically within biologic samples, as was recently
demonstrated for endothelial EV (26). Although the above assays
have the advantage that they allow the qualitative and specific
analysis of EV, the results of BIA may be difficult, if not
impossible, to translate to absolute counts and to particle sizes.
Similar to their isolation, the measurement of EV is
accompanied by restrictions that lie in their small size and their
physicochemical properties. Also here, a gold standard of EV
determination is not clearly defined. Chances are offered by the
exploitation of the palette of surface markers carried by EV
combined with a technique that specifically scans particles in the
correct size range. As technology stands now, flow cytometry still
has the highest potential to become a standard method.
DIFFERENTIATION OF THE CELLULAR
ORIGIN OF EV
As mentioned in the introduction, EV can originate from
virtually every cell or tissue. In the vasculature, the primary cell
types that would release EV eligible as biomarkers are red blood
cells, platelets, leukocytes, and vascular cells. Among those cell
types, red cells and platelets greatly outnumber the others. Thus,
EV derived from red cells and platelets are common in plasma.
Some studies provide an estimation of the relative numbers of EV
from different cell types in blood, yet due to the uncertainties and
variations (as outlined above), the authors refrain from listing
numbers in this overview. For example, it is still debated whether
the platelet-derived EV found in plasma actually originate from
platelets or from megakaryocytes (27).
Crucial for a meaningful exploitation of circulating EV as
biomarkers is the differentiation of cellular origin. Many studies
use surface molecules that function as indicators of the parental
cells of the EV investigated. Although many cells are successfully
being typed using surface markers, the use of such markers
might be accompanied by difficulties. First, EV and in particular
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exosomes, are much smaller, making their measurement by e.g.,
flow cytometry technically more challenging (see below). Second,
while aggregates of whole cells can readily be excluded from
a flow cytometric analysis, the exclusion of EV aggregates is
hampered by the large variation of EV size, meaning that a pair
of 2 smaller EV can have a size similar to another larger EV. This
might give rise to seemingly double-positive EV, which are in
fact aggregates composed of EV from different cellular origins.
Third, cellular activation is often required for EV formation, yet
is also accompanied by activation of proteases (e.g., of the ADAM
family), as is reported for platelets and endothelial cells (EC) (28,
29). Residual protease activity on EVmight lead to loss of surface
markers in time, which is relevant as a physiologic factor, but also
as a pre-analytical variable to be taken into account. The latter
even impacts characterization of EV from isolated cells, as surface
molecules may be lost during storage, giving rise to day-to-day
variations. A fourth difficulty is the availability of cell-specific
markers (and corresponding specific antibodies). Platelets and
EC for example, share quite a number of surface markers (e.g.,
P-selectin, CD31, β3 integrins, thrombospondin, von Willebrand
factor, andmanymore), which complicates a clear differentiation,
particularly in samples where platelet-derived and EC-derived
EV outnumber those from other sources. Platelet- and EC-
derived EV are often distinguished by the use of a common
(e.g., CD31) and a platelet-specific marker (CD41 or CD42),
bearing the risk that platelet-derived EV with poor antibody
binding (e.g., by loss of a marker) can falsely be counted as EC-
derived EV. This also applies in cases that cell-specific EV need
to be isolated from biologic fluids. Since the common techniques
of differential centrifugation or size exclusion chromatography
do not distinguish between EV from different cell types, the
correct use of markers for the enrichment of cell-specific EV
from platelet- or erythrocyte-derived contaminants or protein
aggregates is crucial.
POTENTIAL OF EV AS
BIOMARKERS—RECENT EXAMPLES
Despite the above reservations, surface markers are widely used
in studies exploring levels of particular EV in health and disease.
An accurately adjusted flow cytometer with size calibration and
optics suitable for small particle analysis considerably facilitates
EV determination. The number of flow cytometers that are
capable of measuring EV available on the market is increasing.
By combining small particle measurement with specific surface
markers, information about EV content in biologic fluids can be
obtained with a satisfactory level of accuracy. Several reported
markers used for the determination of EV from particular
cell types are summarized in Table 3. Although a large variety
of techniques for EV analysis is available (Table 2), almost
every patient sample-based study has been performed using
flow cytometry. A recent multicenter collaborative workshop
was organized by the International Society on Thrombosis
and Haemostasis (ISTH) Vascular Biology Standardization
Subcommittee to evaluate a new, universal standardization
protocol to measure platelet EV counts using flow cytometry
TABLE 3 | Examples of markers used for the determination of the cellular origin of
EV.
Cell type Markers References
Monocyte AnxA5, CD11b, CD14, CD31, CD64, CD142 (30–32)
Lymphocyte CD3, CD45 (31)
Neutrophil AnxA5, CD35, CD66b, MPO (32–34)
Platelet AnxA5, CD31, CD41, CD42, CD61 (31)
Megakaryocyte CD62P-, LAMP-1, full-length filamin A (27)
Endothelial cell VCAM-1, CD62E, CD144, CD31, CD41-, CD42- (32, 35)
Red blood cell AnxA5, CD235a (36, 37)
AnxA5, annexin A5; MPO, myeloperoxidase; LAMP, lysosome-associated membrane
protein; VCAM, vascular cell adhesion molecule.
(38). This new standardization protocol was based on side scatter
(SSC) and forward scatter (FSC) of pre-defined beads rather
than only FSC before, dependent on which parameter is used
as the best resolving size parameter in specific flow cytometers
present in the laboratories. The study showed that this bead-
based assay has potential for standardization of measurement of
platelet EV numbers, however this procedure is not suitable to
measure particle size.
Altered levels of EV were found in cohorts of patients with
variety of cardiovascular diseases. Several recent reviews provide
an excellent and comprehensive overview of the relevant studies
(3, 7, 39–41) and highlights of original work are listed in Table 4.
In general, the origin of the EV investigated in most studies
is derived from 3 main cell types: endothelial cells, leukocytes,
and platelets. This is not surprising, since all 3 cell types are
in direct contact with the blood. In addition, the endothelial
lining of the vessel wall constitutes a huge surface (approx. 7,000
m2) and in the case of (systemic) inflammation, cytokines may
increase the activation state of the endothelium, giving rise to the
release of numerous EV. The same counts for platelets, since their
sheer numbers combined with their capability to release EV upon
activation can result in steep increases in EV numbers during
pathologic conditions such as arterial and venous thrombosis.
When surface markers become more defined and the analysis
techniques more refined, also EV from rare cell types that are
underrepresented in biologic samples may be detected.
Most of the studies show a positive correlation between EV
counts and the cardiovascular disorder investigated, regardless
of the cell type of origin. This may reflect the common
observation that cells show an increase release of EV after
activation. EVs have shown to be upregulated in patients with
endothelial dysfunction or atherosclerosis (42, 59), in patients
with deep vein thrombosis or pulmonary embolism (60–62),
in patients with cerebrovascular diseases(63–66) or in patients
that show cardiovascular risk factors like type-2 diabetes mellitus
(67), severe hypertension (68) or obesity (69). Determining the
EV’s parent cells harbors the possibility to obtain additional
information about the pathophysiology of a particular disorder.
For example, in a small case-control study of one of the study
arms of the PREDIMED trial with participants following a
Mediterranean Diet, the EV levels of different cell types were
measured. Participants suffering a cardiovascular event (CVE)
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TABLE 4 | Cardiovascular disorders (CVD) with involvement of EV.
Pathologic setting EV from cell types involved References
EV as risk factor for
CVD
Endothelial cells (14, 36, 42–48)
Platelets (14, 36, 42, 46–48)
Leukocytes (unspecified) (42, 46, 47)
Monocytes (46, 48)
Lymphocytes (43)
Hematopoietic cells (43)
Smooth muscle cells (43)
Erythrocytes (36)
Vascular calcification Smooth muscle cells (49–52)
Macrophages (53)
Endothelial cells (54)
Platelets (54)
Leukocytes (unspecified) (54)
Coronary artery
disease and acute
coronary syndrome
Endothelial cells (37, 44, 55–58)
Platelets (44, 55, 57, 58)
Erythrocytes (37)
Leukocytes (unspecified) (55, 58)
Monocytes (31)
within 1 year of intervention, showed increased EV release
from lymphocytes and smooth muscle cells. Participants that
did not have a future CVE within the follow-up time showed
reduced EV release from these cells (43). In a case-control study
at the NIH Stroke program, even different subtypes of EVs
from endothelial parent cells could be distinguished. This study
compared endothelial cell-derived EV levels in 20 patients with a
mild stroke (NIHSS score< 5) to the EV levels of 21 patients with
moderate to severe stroke (NIHSS score≥ 5), and to the levels of
23 age-matched healthy volunteers. Using flow cytometry, they
observed significantly higher phosphatidyl serine+ EV counts in
patients compared to the controls, and all endothelial derived
EV counts were elevated in the moderate to severe stroke
group compared to controls. In patients with acute ischemic
stroke, three endothelial cell microparticle (EMP) phenotypes
(Endoglin+ EMP, phosphatidyl serine+ EMP, and ICAM-1+
EMP) correlated significantly with brain lesion volume, with
ICAM-1+ EMP (P = 0.002) showing the strongest correlation.
These data combined suggest a possible role of endothelial-
derived EV numbers as a biomarker for severity and brain lesion
size in patients with ischemic stroke (64).
Endothelial dysfunction is an independent predictor of
vascular disease. Therefore, quantitative measurements of
CD31+/Annexin A5+ EVs were assessed by Sinning and
colleagues in patients with stable coronary artery disease (CAD).
EV levels were higher in patients that later developed a major
adverse cardiovascular and cerebral event (44). This study
also finds that the presence of diabetes and male gender are
significantly positively correlated to the number of EVs, a factor
that has to be taken into account during risk stratification.
In addition, since EVs can be purified, their numbers and
contents can be enriched manifold, which opens the possibility
for the identification and determination of biomarkers that were
previously too dilute to be measured in biologic fluids. Some
studies have exploited this to identify miRNAs with prognostic
value for cardiovascular diseases (14, 36). EVs of thrombin-
stimulated platelets have elevated levels of miR-223 in complex
with Argonaute 2, are taken up by HUVEC cells in vitro, and
regulate gene expression levels through regulatory elements in
the 3′UTR region of two specific mRNAs (70). This is only one of
the examples in which platelets can alter specific gene regulation
in HUVEC cells.
Moreover, the proteins cystatin C, serpin G1 and F2, and
CD14 found in EVs have been identified as potential biomarkers
by Kanhai et al. in 2013, using the Athero-Express discovery
cohort (71). This was the first large, single-center cohort of
1,060 patients, to describe the protein content of EVs is related
to increased risk of secondary cardiovascular events. Increased
levels of cystatin C, serpin F2, and CD14 were correlated to
an increased risk of myocardial infarction, vascular events and
all-cause mortality, whereas increased levels of CD14 was also
correlated to an increased risk of the occurrence of an ischemic
stroke. This study only takes total EV protein levels in account,
and not the number of EV.
Another prospective single-center cohort study showed that
the EV protein levels polygenic immunoglobulin receptor,
cystatin C and complement C5a were independently associated
with acute coronary syndrome (72). This study also indicates
an important discrepancy between male and female patients,
where male patients show a strong correlation between the
aforementioned proteins and ACS, whereas female patients did
not.
Patients at risk for CVD with high LDL levels are often treated
with statins. Statins prevent cardiovascular events, possibly
not only by reducing plasma LDL levels. The METEOR trial
aims to determine the effect of rosuvastatin on subclinical
atherosclerosis. Patient serum samples and LDL-EVs were
analyzed for their protein content of von Willebrand factor
(vWF), Serpin C1, and plasminogen. Rosuvastatin-treated
patients have higher levels of plasminogen and vWF in LDL-
associated EVs, serum plasminogen levels were also increased
but to a lesser extent, and serum vWF levels were not increased
(73). This study concludes that this could be a possible new
intermediate between statin therapy and coagulation.
Possibly the most studied potential biomarker is the
coagulation potential of EVs exposing tissue factor (TF+ EV)
in cancer patients, to evaluate the relative risk on developing
venous thromboembolism (VTE) which is a complication in
many cancer patients. In a multinational, prospective cohort
study, the procoagulant activity of TF+ EV was evaluated using
an in-house TF+ EV activity assay based on fibrin generation.
The TF+ EV activity was measured in patients with various
types of advanced cancer, and correlated with the development
of venous thromboembolism (VTE). A high fibrin generation test
outcome was associated with a two-fold increased risk for VTE,
with the strongest association in patients with pancreatic cancer
(four-fold increase) compared to patients with other tumor types
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(1.5 fold increase). The activity of TF+ EV measured using the
fibrin generation test correlated poorly with the more commonly
used TF-dependent Xa assay (74). However, there are also studies
that do not find correlation of EVs with risk for VTE (75), or
only a correlation with mortality but not with thrombosis (76).
Therefore the role of TF+ EV as biomarker for VTE in cancer
patients remains a matter of debate. Not only EVs derived from
cancer cells but also EVs from monocytes expose TF. Although
platelets were found to express TF (77), EVs from platelets and
erythrocytes lack TF but did induce thrombin generation in a
FXII-dependent matter (78).
Despite these examples of protein content in or on EVs, most
of the current studies are limited to absolute counts of EV from
particular cell types. The number of studies showing correlations
or associations of EV numbers with disease prognosis, severity
or occurrence is steadily increasing. It must be noted that the
majority of studies have a relatively low number of subjects
included in the investigation. The largest study to date on EV
numbers in CVD is the study of Amabile et al. (2014) where 844
individuals in the Framingham Offspring cohort were studied
(45). In this cohort, endothelial-derived EVs were associated with
the presence of several cardiometabolic risk factors, including
higher triglyceride levels, hypertension, andmetabolic syndrome.
The highest correlation was found with elevated triglycerides.
However, this study only focused on large vesicles ≥ 500 nm,
thereby risking that a substantial amount of the sample consists
of apoptotic bodies.
Another complication is the lack of standardization of sample
processing and measurement, making it difficult to compare
studies from different laboratories. The same counts for the
selection of surface markers analyzed and the corresponding
allocation to the EV’s parent cell types. A final issue is the
heterogeneity of the sample populations investigated, meaning
that there are quite some indications that EV are associated with
a particular cardiovascular disease, yet hard evidence for such
association in large cohorts of defined subjects is still largely
lacking. It has to be noted that the above complications largely
apply for biomarker research in general.
CONCLUDING REMARKS
Without doubt, the potential of EV as biomarkers is considerable.
They may contain information about the original tissues, the
pathophysiologic context and the severity of disease. On the
other hand, the field is still relatively young and the progress
in technologic development for accurate analysis is somewhat
lagging behind the desires and ambitions of the investigators
working in the area. Still, there is increasing consensus about
the standardization of sample preparation and analysis of EV,
meaning that studies are becoming more and more reliable
and comparison between study locations becomes increasingly
feasible. Taken together, interesting and exciting times are
awaiting us, as EV do seem to be a big step toward the highly
anticipated liquid biopsies.
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